[CAS NO. 117690-79-6] LY255283
PRODUCTS SPECIFICATIONS [117690-79-6]
DESCRIPTION [117690-79-6]
Overview
| MDL | MFCD00876422 |
|---|---|
| Molecular Weight | 360.45 |
| Molecular Formula | C19H28N4O3 |
| SMILES | CC(C1=CC(CC)=C(OCCCCCC(C2=NNN=N2)(C)C)C=C1O)=O |
1 Publications Citing Use of MCE
Summary
IC50 & Target
|
LTB 4 ~100 nM (IC 50 , LTB 4 binds to guinea pig lung membranes) |
In Vitro
LY255283 competitively reduces conlractilc responses of lung parcnchyma to LTB, (pA
2
= 7.2)
[2]
.
LY255283 (10 μM, 7 days) significantly suppresses the invasiveness of highly aggressive 253 J-BV bladder cancer cells
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [4]
| Cell Line: | 253 J-BV cells. |
| Concentration: | 5 or 10 μM. |
| Incubation Time: | 7 days. |
| Result: | Inhibition of BLT2 signaling attenuates aggressive migration by 253 J-BV cells. |
In Vivo
LY255283 (3, 30 mg/kg) ameliorates lipopolysaccharide-induced ARDS in pigs, possibly by blocking the recruitment of activated PMNs into alveoli in a dose-dependent fashion
[3]
.
LY255283 (2.5 mg/kg, ip) inhibits transitional cell carcinoma metastasis in mice models. The result suggests that a BLT2–Nox–ROS–NF–κB cascade plays a critical role in bladder cancer invasion and metastasis
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Mice (253 J-BV cells injected) [4] . |
| Dosage: | 2.5 mg/kg. |
| Administration: | IP injected 3 and 5 days after injection of cells. |
| Result: | By 12 weeks after injection, in mice treated with LY255283 only 0-3 nodules formed per lung, and histological analysis confirmed that the number of micrometastatic lesions was markedly reduced. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 100 mg/mL ( 277.43 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7743 mL | 13.8715 mL | 27.7431 mL |
| 5 mM | 0.5549 mL | 2.7743 mL | 5.5486 mL |
| 10 mM | 0.2774 mL | 1.3872 mL | 2.7743 mL |
References
- [1] R M Schultz, et al. Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production. Prostaglandins Leukot Essent Fatty Acids. 1991 Aug;43(4):267-71.
- [2] S A Silbaugh, et al. Pulmonary actions of LY255283, a leukotriene B4 receptor antagonist. Eur J Pharmacol. 1992 Nov 13;223(1):57-64.
- [3] P S Wollert, et al. LY255283, a novel leukotriene B4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery. 1993 Aug;114(2):191-8.
- [4] Eun-Young Kim, et al. BLT2 promotes the invasion and metastasis of aggressive bladder cancer cells through a reactive oxygen species-linked pathway. Free Radic Biol Med. 2010 Sep 15;49(6):1072-81.